Peer Review History

Original SubmissionAugust 17, 2021
Decision Letter - Sajid Bashir Soofi, Editor

PONE-D-21-26679Determinants of mammography screening participation – A cross-sectional analysis of the German population-based Gutenberg Health Study (GHS)PLOS ONE

Dear Dr. Roman Pokora,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

Thank you for your interesting article, but it needs Minor Revision, as suggested by expert reviewers. Please address the concerns raised by the reviewers and resubmit the revised version. 

==============================

Please submit your revised manuscript by Apr 03 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Sajid Bashir Soofi

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/fileid=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf".

2. Thank you for stating the following financial disclosure:

“The GHS is funded through contract AZ 961-386261/733 from the government of Rhineland-Palatinate (“Stiftung Rheinland-Pfalz für Innovation”); the research programs “Wissen schafft Zukunft” and “Center for Translational Vascular Biology” of the Johannes Gutenberg University Mainz; and its contract with Boehringer Ingelheim and Philips Medical Systems, including an unrestricted grant for the GHS. This study was also supported by grant BMBF 01EO1503 from the Federal Ministry of Education and Research.”

Please state what role the funders took in the study.  If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.""

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. Thank you for stating the following in the Competing Interests section:

“Dr. Wild reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Novartis Pharma, grants from Philips Medical Systems, grants from Bayer AG, grants and personal fees from Sanofi-Aventis, grants and personal fees from Bayer Vital, grants and personal fees from Daiichy Sankyo, grants and personal fees from Bayer Health Care, personal fees from AstraZeneca, personal fees and non-financial support from DiaSorin, non-financial support from I.E.M., outside the submitted work; Dr. Schuster reports the professorship for ophthalmic healthcare research endowed by ‘Stiftung Auge’ and financed by ‘Deutsche Ophthalmologische Gesellschaft’ and ‘Berufsverband der Augenarzte Deutschlands e.V.’ Schuster AK received research funding from Allergan, Bayer Vital, Novartis, PlusOptix and Heidelberg Engineering; Dr. Singer reports personal fees from Pfizer, personal fees from Bristol-Myers Squibb, personal fees from Boehringer-Ingelheim, personal fees from Lilly, outside the submitted work; Dr. Wollschläger reports grants from German Federal Ministry of Education and Research, during the conduct of the study. All other authors declare no conflict of interest.”

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: ""This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Please address the point-by-point comments raised by reviewers.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: It is a technically sound study, well conducted and a well written manuscript. Would be nice to add a little detail about the mammography invitation process for the non-German reader. I feel it would be important to explore perhaps as a separate study, the reasons behind the decrease in mammography (recently) with higher education. Are they accessing bad information on social media or misinterpreting information about radiation exposure etc. This may inform further decisions and the invitation process may need to have more detailed information on dispelling the myths.

Reviewer #2: The article addresses an important matter regarding participation in screening mammography programs. Participation in screening programs is mostly affected by knowledge/awareness, access and personal beliefs. Being a smoker or alcohol consumer, BMI etc can have a direct relation with increasing breast cancer risk, but PARTICIPATING or not participating in a free mammography screening program due to these factors doesn't make sense. Also p-values and data could not be found so exact significance of these variables could not be ascertained.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Response to the editor:

Dear Mr. Soofi,

Thank you for considering our manuscript entitled “Determinants of mammography screening participation – A cross-sectional analysis of the German population-based Gutenberg Health Study (GHS)” by Pokora, Büttner, Schulz, Schuster, Merzenich, Teifke, Michal, Lackner, Münzel, Zeissig, Wild, Singer, and Wollschläger for publication and thank you for your good and valuable comments. The comments to the reviewer are in the document ‚Response to Reviewers‘. We responded all the comments and we included our comments to you in this cover letter. The comments to you are in black font, our replies in black font italic and underlined:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/fileid=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf".

Answer: Thank you. We revised the file naming.

2. Thank you for stating the following financial disclosure:

“The GHS is funded through contract AZ 961-386261/733 from the government of Rhineland-Palatinate (“Stiftung Rheinland-Pfalz für Innovation”); the research programs “Wissen schafft Zukunft” and “Center for Translational Vascular Biology” of the Johannes Gutenberg University Mainz; and its contract with Boehringer Ingelheim and Philips Medical Systems, including an unrestricted grant for the GHS. This study was also supported by grant BMBF 01EO1503 from the Federal Ministry of Education and Research.”

Please state what role the funders took in the study. If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.""

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

Answer: We included the role the funders took in the study and added the sentence.

Change of financial disclosure statement:

“The GHS is funded through contract AZ 961-386261/733 from the government of Rhineland-Palatinate (“Stiftung Rheinland-Pfalz für Innovation”); the research programs “Wissen schafft Zukunft” and “Center for Translational Vascular Biology” of the Johannes Gutenberg University Mainz; and its contract with Boehringer Ingelheim and Philips Medical Systems, including an unrestricted grant for the GHS. This study was also supported by grant BMBF 01EO1503 from the Federal Ministry of Education and Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

3. Thank you for stating the following in the Competing Interests section:

“Dr. Wild reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Novartis Pharma, grants from Philips Medical Systems, grants from Bayer AG, grants and personal fees from Sanofi-Aventis, grants and personal fees from Bayer Vital, grants and personal fees from Daiichy Sankyo, grants and personal fees from Bayer Health Care, personal fees from AstraZeneca, personal fees and non-financial support from DiaSorin, non-financial support from I.E.M., outside the submitted work; Dr. Schuster reports the professorship for ophthalmic healthcare research endowed by ‘Stiftung Auge’ and financed by ‘Deutsche Ophthalmologische Gesellschaft’ and ‘Berufsverband der Augenarzte Deutschlands e.V.’ Schuster AK received research funding from Allergan, Bayer Vital, Novartis, PlusOptix and Heidelberg Engineering; Dr. Singer reports personal fees from Pfizer, personal fees from Bristol-Myers Squibb, personal fees from Boehringer-Ingelheim, personal fees from Lilly, outside the submitted work; Dr. Wollschläger reports grants from German Federal Ministry of Education and Research, during the conduct of the study. All other authors declare no conflict of interest.”

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: ""This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Answer: We included the role the funders took in the study and added the sentence.

Change of competing interest statement:

“Dr. Wild reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Novartis Pharma, grants from Philips Medical Systems, grants from Bayer AG, grants and personal fees from Sanofi-Aventis, grants and personal fees from Bayer Vital, grants and personal fees from Daiichy Sankyo, grants and personal fees from Bayer Health Care, personal fees from AstraZeneca, personal fees and non-financial support from DiaSorin, non-financial support from I.E.M., outside the submitted work; Dr. Schuster reports the professorship for ophthalmic healthcare research endowed by ‘Stiftung Auge’ and financed by ‘Deutsche Ophthalmologische Gesellschaft’ and ‘Berufsverband der Augenarzte Deutschlands e.V.’ Schuster AK received research funding from Allergan, Bayer Vital, Novartis, PlusOptix and Heidelberg Engineering; Dr. Singer reports personal fees from Pfizer, personal fees from Bristol-Myers Squibb, personal fees from Boehringer-Ingelheim, personal fees from Lilly, outside the submitted work; Dr. Wollschläger reports grants from German Federal Ministry of Education and Research, during the conduct of the study. All other authors declare no conflict of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.”

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Answer: Unfortunately, we cannot provide a public minimum data set for data protection reasons. In principle, the GHS is subject to the regulations of the general data protection regulation (DSGVO) when passing on personal data. The data may not be forwarded to third parties without the consent of the participants. At the GHS, there is a separate consent for disclosure to cooperation partners. However, if this consent is given, the data can only be passed on in the context of a scientific cooperation if the GHS Steering Committee deems it useful and necessary from a scientific point of view. However, there are also participants who have not agreed in principle to data being passed on. For them, it does not go under any circumstances. For this reason, we have updated our Data Availability statement as follows.

"The GHS data cannot be made publicly available because participants were assured that the data would only be used for scientific research purposes, and therefore the informed consent included only limited data sharing. At GHS, there is a separate consent to share data with collaborators. However, if this consent is given, the data can only be shared as part of a scientific collaboration if the GHS Steering Committee deems it appropriate and necessary from a scientific perspective. However, there are also participants who have not consented to the sharing of data in principle. For these participants, data can only be analyzed on-site. Available data are available to researchers who meet the criteria for access to confidential data from the GHS Coordinating Principal Investigator (philipp.wild@unimedizin-mainz.de). More detailed contact information can be found on the home pages of the GHS

(http://www.gutenberghealthstudy.org/ghs/overview.html?L=1)."

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Thank you. We reviewed the reference list and corrected the mistakes.

Best regards,

Roman Pokora

Response to the reviewer:

Thank you for reviewing our manuscript. Please find attached our point-by-point response to the comments. Reviewer comments are in black font, Author replies in black font italic and underlined.

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: I Don't Know

________________________________________

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

________________________________________

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: It is a technically sound study, well conducted and a well written manuscript. Would be nice to add a little detail about the mammography invitation process for the non-German reader.

Answer: We added in the introduction (line 67ff) a part about the invitation process.

“Eligible women are informed every two years by an invitation letter from one of 14 Central Offices which organize the mammography screening program nationwide. A detailed information brochure is sent out with the invitation. The brochure serves as a decision-making aid and provides information on the examination procedure, on breast cancer, and on possible advantages as well as disadvantages of participating in a screening program.”

I feel it would be important to explore perhaps as a separate study, the reasons behind the decrease in mammography (recently) with higher education. Are they accessing bad information on social media or misinterpreting information about radiation exposure etc. This may inform further decisions and the invitation process may need to have more detailed information on dispelling the myths.

Answer: We agree with the reviewer that specifically the groups that do not participate would need to be examined more closely in a qualitative study. It would also be interesting to find out where these groups get their information.

Reviewer #2: The article addresses an important matter regarding participation in screening mammography programs. Participation in screening programs is mostly affected by knowledge/awareness, access and personal beliefs. Being a smoker or alcohol consumer, BMI etc can have a direct relation with increasing breast cancer risk, but PARTICIPATING or not participating in a free mammography screening program due to these factors doesn't make sense.

Answer: In the absence of better variables, we included the variables smoking, BMI, alcohol consumption, etc. as a proxy for health behaviors in our model.

Also p-values and data could not be found so exact significance of these variables could not be ascertained.

Answer: We understand the concerns from the reviewer. We do not report p-values anywhere in the manuscript. The reasons for doing so:

1. The sample size is sufficiently large that even seemingly trivial differences are likely to be statistically significant.

2. P-values are commonly misinterpreted as the probability that the test hypothesis is true, or as the probability that observed association is due to chance alone. Both are false.

In sum, in the present study we do not believe that adding P values would help readers to get a better sense of whether the reported characteristics differ across women, or that p-values and significance testing would add valuable information beyond the reported confidence intervals.

We hope that the explanations will satisfy the reviewers and that the editors will appreciate our efforts to conform with the STOBE statement and the position of the American Statistical Association (2016). Enclosed we send the result tables with the p-values.

Thank you for reviewing our manuscript and for the helpful comments. We are looking forward to your reply.

best regards on behalf of all authors

Roman Pokora

Attachments
Attachment
Submitted filename: Response to reviewers.docx
Decision Letter - Edward Jay Trapido, Editor

Determinants of mammography screening participation – A cross-sectional analysis of the German population-based Gutenberg Health Study (GHS)

PONE-D-21-26679R1

Dear Dr. Pokora,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Edward Jay Trapido, ScD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: I Don't Know

Reviewer #3: No

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

Reviewer #3: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

**********

Formally Accepted
Acceptance Letter - Edward Jay Trapido, Editor

PONE-D-21-26679R1

Determinants of mammography screening participation – A cross-sectional analysis of the German population-based Gutenberg Health Study (GHS)

Dear Dr. Pokora:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Edward Jay Trapido

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .